{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T22:57:38Z","timestamp":1776293858355,"version":"3.50.1"},"reference-count":85,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T00:00:00Z","timestamp":1522022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fibrodysplasia ossificans progressiva (FOP) is a rare genetic condition characterized by progressive extra-skeletal ossification leading to cumulative and severe disability. FOP has an extremely variable and episodic course and can be induced by trauma, infections, iatrogenic harms, immunization or can occur in an unpredictable way, without any recognizable trigger. The causative gene is ACVR1, encoding the Alk-2 type I receptor for bone morphogenetic proteins (BMPs). The signaling is initiated by BMP binding to a receptor complex consisting of type I and II molecules and can proceed into the cell through two main pathways, a canonical, SMAD-dependent signaling and a p38-mediated cascade. Most FOP patients carry the recurrent R206H substitution in the receptor Glycine-Serine rich (GS) domain, whereas a few other mutations are responsible for a limited number of cases. Mutations cause a dysregulation of the downstream BMP-dependent pathway and make mutated ACVR1 responsive to a non-canonical ligand, Activin A. There is no etiologic treatment for FOP. However, many efforts are currently ongoing to find specific therapies targeting the receptor activity and the downstream aberrant pathway at different levels or targeting cellular components and\/or processes that are important in modifying the local environment leading to bone neo-formation.<\/jats:p>","DOI":"10.3390\/ijms19040989","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T12:08:25Z","timestamp":1522066105000},"page":"989","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The Horizon of a Therapy for Rare Genetic Diseases: A \u201cDruggable\u201d Future for Fibrodysplasia Ossificans Progressiva"],"prefix":"10.3390","volume":"19","author":[{"given":"Serena","family":"Cappato","sequence":"first","affiliation":[{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Giacopelli","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ravazzolo","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8415-3802","authenticated-orcid":false,"given":"Renata","family":"Bocciardi","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, 16132 Genoa, Italy"},{"name":"UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/humu.20868","article-title":"Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1","volume":"30","author":"Kaplan","year":"2009","journal-title":"Hum Mutat."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000365770","article-title":"Fibrodysplasia ossificans progressiva: Clinical course, genetic mutations and genotype-phenotype correlation","volume":"5","year":"2014","journal-title":"Mol. Syndromol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","article-title":"A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva","volume":"38","author":"Shore","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.cellsig.2011.04.004","article-title":"Homomeric and heteromeric complexes among TGF-\u03b2 and BMP receptors and their roles in signaling","volume":"23","author":"Ehrlich","year":"2011","journal-title":"Cell. Signal."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0092-8674(00)80116-6","article-title":"The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors","volume":"86","author":"Wang","year":"1996","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/ejhg.2008.178","article-title":"Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: Confirmations and advancements","volume":"17","author":"Bocciardi","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10067-009-1283-z","article-title":"Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva","volume":"29","author":"Ratbi","year":"2010","journal-title":"Clin. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","article-title":"ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A","volume":"7","author":"Hatsell","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15438","DOI":"10.1073\/pnas.1510540112","article-title":"Neofunction of ACVR1 in fibrodysplasia ossificans progressiva","volume":"112","author":"Hino","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-017-0659-4","article-title":"International physician survey on management of FOP: A modified Delphi study","volume":"12","author":"Baujat","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3181\/00379727-211-43970","article-title":"Recombinant human bone morphogenetic protein (rhBMP) induced heterotopic bone development in vivo and in vitro","volume":"211","author":"Urist","year":"1996","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2106\/JBJS.H.01177","article-title":"Identification of progenitor cells that contribute to heterotopic skeletogenesis","volume":"91","author":"Lounev","year":"2009","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0002-9440(10)63372-X","article-title":"Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype","volume":"165","author":"Kan","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1359\/JBMR.050305","article-title":"Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA","volume":"20","author":"Billings","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1359\/jbmr.060215","article-title":"Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP)","volume":"21","author":"Fiori","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1074\/jbc.M801681200","article-title":"Constitutively activated ALK2 and increased SMAD1\/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva","volume":"284","author":"Fukuda","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_17","first-page":"3462","article-title":"The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization","volume":"119","author":"Shen","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbrc.2008.10.093","article-title":"A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor","volume":"377","author":"Fukuda","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22542","DOI":"10.1074\/jbc.M109.094557","article-title":"Molecular consequences of the ACVR1R206H mutation of fibrodysplasia ossificans progressiva","volume":"285","author":"Song","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bbrc.2011.03.001","article-title":"A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H","volume":"407","author":"Ohte","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1093\/hmg\/ddu255","article-title":"ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant","volume":"23","author":"Haupt","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bone.2018.01.002","article-title":"Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish","volume":"109","author":"Mucha","year":"2018","journal-title":"Bone"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/nm.1888","article-title":"BMP type I receptor inhibition reduces heterotopic ossification","volume":"14","author":"Yu","year":"2008","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1016\/j.bmcl.2008.06.052","article-title":"Structure-activity relationship study of bone orphogenetic protein (BMP) signaling inhibitors","volume":"18","author":"Cuny","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sanvitale, C.E., Kerr, G., Chaikuad, A., Ramel, M.C., Mohedas, A.H., Reichert, S., Wang, Y., Triffitt, J.T., Cuny, G.D., and Yu, P.B. (2013). A new class of small molecule inhibitor of BMP signaling. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062721"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/cb300655w","article-title":"Development of n ALK2-biased BMP type I receptor kinase inhibitor","volume":"8","author":"Mohedas","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1021\/jm501177w","article-title":"Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants","volume":"57","author":"Mohedas","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/dvg.20201","article-title":"Generation of a mouse with conditionally activated signaling through the BMP eceptor, ALK2","volume":"44","author":"Fukuda","year":"2006","journal-title":"Genesis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/j.1460-2075.1995.tb07214.x","article-title":"GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex","volume":"14","author":"Wieser","year":"1995","journal-title":"EMBO J."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Williams, E., and Bullock, A.N. (2017). Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone.","DOI":"10.1016\/j.bone.2017.09.004"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jcf.2015.06.002","article-title":"Targeting ion channels in cystic fibrosis","volume":"14","author":"Mall","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cytogfr.2015.11.005","article-title":"Structural insights into BMP receptors: Specificity, activation and inhibition","volume":"27","author":"Yadin","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/ajmg.a.38326","article-title":"Drug discovery and development for rare genetic disorders","volume":"173","author":"Sun","year":"2017","journal-title":"Am. J. Med. Genet A"},{"key":"ref_34","first-page":"26","article-title":"Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice","volume":"31","author":"Yamamoto","year":"2013","journal-title":"J. Bone Miner. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1750-1172-8-163","article-title":"Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: An open-labeled clinical trial","volume":"8","author":"Kitoh","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41467-018-02872-2","article-title":"Activin-dependent signaling in fibro\/adipogenic progenitors causes fibrodysplasia ossificans progressiva","volume":"9","author":"Yamamoto","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1172\/JCI93521","article-title":"Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva","volume":"127","author":"Hino","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kaplan, F.S., Zeitlin, L., Dunn, S.P., Benor, S., Hagin, D., Al Mukaddam, M., and Pignolo, R.J. (2017). Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases. Bone.","DOI":"10.1016\/j.bone.2017.12.011"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/nm.2252","article-title":"Conversion of vascular endothelial cells into multipotent stem-like cells","volume":"16","author":"Medici","year":"2010","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/jbmr.1691","article-title":"The role of endothelial-mesenchymal transition in heterotopic ossification","volume":"27","author":"Medici","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"366ra163","DOI":"10.1126\/scitranslmed.aaf1090","article-title":"Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification","volume":"8","author":"Dey","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/jbmr.1562","article-title":"Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification","volume":"27","author":"Wosczyna","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4939-3810-0_18","article-title":"FACS Fractionation and Differentiation of Skeletal-Muscle Resident Multipotent Tie2+ Progenitors","volume":"1460","author":"Biswas","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrrheum.2010.122","article-title":"Inherited human diseases of heterotopic bone formation","volume":"6","author":"Shore","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/JOE-11-0048","article-title":"The skeleton: A multi-functional complex organ. The growth plate chondrocyte and endochondral ossification","volume":"211","author":"Mackie","year":"2011","journal-title":"J. Endocrinol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1359\/jbmr.091110","article-title":"ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation","volume":"25","author":"Visser","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/stem.1633","article-title":"Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification","volume":"32","author":"Culbert","year":"2014","journal-title":"Stem Cells"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2106\/00004623-200300002-00017","article-title":"Molecular mechanisms regulating chondroblast differentiation","volume":"85","author":"Hoffman","year":"2003","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Pacifici, M. (2017). Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial. Bone.","DOI":"10.1016\/j.bone.2017.08.010"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jor.20985","article-title":"Inhibition of ectopic bone formation by a selective retinoic acid receptor alpha-agonist: A new therapy for heterotopic ossification?","volume":"28","author":"Shimono","year":"2010","journal-title":"J. Orthop. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nm.2334","article-title":"Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-\u03b3 agonists","volume":"17","author":"Shimono","year":"2011","journal-title":"Nat. Med."},{"key":"ref_52","first-page":"1243","article-title":"Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema","volume":"10","author":"Hind","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bone.2016.02.008","article-title":"Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent","volume":"90","author":"Sinha","year":"2016","journal-title":"Bone"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/jbmr.2820","article-title":"Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation","volume":"31","author":"Chakkalakal","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1750-1172-8-145","article-title":"Identification and characterization of regulatory elements in the promoter of ACVR1, the gene mutated in Fibrodysplasia Ossificans Progressiva","volume":"8","author":"Giacopelli","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1242\/dmm.023929","article-title":"High-throughput screening for modulators of ACVR1 transcription: Discovery of potential therapeutics for fibrodysplasia ossificans progressiva","volume":"9","author":"Cappato","year":"2016","journal-title":"Dis. Model Mech."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4161\/rna.8.5.16153","article-title":"MicroRNA-30c promotes human adipocyte differentiation and co-represses PAI-1 and ALK2","volume":"8","author":"Karbiener","year":"2011","journal-title":"RNA Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3390\/ijms13022063","article-title":"ACVR1, a therapeutic target of fibrodysplasia ossificans progressiva, is negatively regulated by miR-148a","volume":"13","author":"Song","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Mura, M., Cappato, S., Giacopelli, F., Ravazzolo, R., and Bocciardi, R. (2012). The role of the 3\u2032UTR region in the regulation of the ACVR1\/Alk-2 gene expression. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050958"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"23796","DOI":"10.1074\/jbc.M114.577387","article-title":"MicroRNA-130a is up-regulated in mouse liver by iron deficiency and targets the bone morphogenetic protein (BMP) receptor ALK2 to attenuate BMP signaling and hepcidin transcription","volume":"289","author":"Wu","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hep.27543","article-title":"Regulatory MiR-148a-ACVR1\/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma","volume":"61","author":"Li","year":"2015","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Fokkema","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Shi, S., Cai, J., de Gorter, D.J., Sanchez-Duffhues, G., Kemaladewi, D.U., Hoogaars, W.M., Aartsma-Rus, A., \u2018t Hoen, P.A.C., and ten Dijke, P. (2013). Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: Inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069096"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/gt.2011.152","article-title":"Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting","volume":"19","author":"Kaplan","year":"2012","journal-title":"Gene Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/gt.2011.193","article-title":"Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva","volume":"19","author":"Takahashi","year":"2012","journal-title":"Gene Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00003086-199801000-00005","article-title":"Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva","volume":"346","author":"Gannon","year":"1998","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1053\/hupa.2001.26464","article-title":"Mast cell involvement in fibrodysplasia ossificans progressiva","volume":"32","author":"Gannon","year":"2001","journal-title":"Hum. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.semcdb.2015.12.013","article-title":"Granting immunity to FOP and catching heterotopic ossification in the Act","volume":"49","author":"Kaplan","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cytogfr.2009.02.007","article-title":"Activin and related proteins in inflammation: Not just interested bystanders","volume":"20","author":"Phillips","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/icb.2011.32","article-title":"When versatility matters: Activins\/inhibins as key regulators of immunity","volume":"90","author":"Soldevila","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wang, H., Behrens, E.M., Pignolo, R.J., and Kaplan, F.S. (2017). ECSIT links TLR and BMP signaling in FOP connective tissue progenitor cells. Bone.","DOI":"10.1016\/j.bone.2017.12.024"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1634\/stemcells.2008-0576","article-title":"Dysregulation of local stem\/progenitor cells as a common cellular mechanism for heterotopic ossification","volume":"27","author":"Kan","year":"2009","journal-title":"Stem Cells"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Brennan, T.A., Lindborg, C.M., Bergbauer, C.R., Wang, H., Kaplan, F.S., and Pignolo, R.J. (2017). Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP). Bone.","DOI":"10.1016\/j.bone.2017.08.023"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/jcb.23259","article-title":"Substance P signaling mediates BMP-dependent heterotopic ossification","volume":"112","author":"Kan","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Convente, M.R., Chakkalakal, S.A., Yang, E., Caron, R.J., Zhang, D., Kambayashi, T., Kaplan, F.S., and Shore, E.M. (2017). Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an ACVR1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva. J. Bone Miner. Res.","DOI":"10.1002\/jbmr.3304"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2106\/JBJS.F.00472","article-title":"Hematopoietic stem-cell contribution to ectopic skeletogenesis","volume":"89","author":"Kaplan","year":"2007","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Del Zotto, G., Antonini, F., Azzari, I., Ortolani, C., Tripodi, G., Giacopelli, F., Cappato, S., Moretta, L., Ravazzolo, R., and Bocciardi, R. (2017). Peripheral blood mononuclear cell immunophenotyping in fibrodysplasia ossificans progressiva patients: Evidence for monocyte DNAM1 up-regulation. Cytom. B Clin. Cytom.","DOI":"10.1002\/cyto.b.21594"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI84433","article-title":"Hypoxia-dependent regulation of inflammatory pathways in immune cells","volume":"126","author":"Taylor","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1574888X09666131230142459","article-title":"Roles of hypoxia during the chondrogenic differentiation of mesenchymal stem cells","volume":"9","author":"Shang","year":"2014","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"E338","DOI":"10.1073\/pnas.1515397113","article-title":"Inhibition of Hif1\u03b1 prevents both trauma-induced and genetic heterotopic ossification","volume":"113","author":"Agarwal","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/jbmr.2848","article-title":"Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling","volume":"31","author":"Wang","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e89805","DOI":"10.1172\/jci.insight.89805","article-title":"mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration","volume":"1","author":"Agarwal","year":"2016","journal-title":"JCI Insight"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kaplan, F.S., Andolina, J.R., Adamson, P.C., Teachey, D.T., Finklestein, J.Z., Ebb, D.H., Whitehead, B., Jacobs, B., Siegel, D.M., and Keen, R. (2017). Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases. Bone.","DOI":"10.1016\/j.bone.2017.07.019"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13023-018-0761-2","article-title":"Principles for interactions with biopharmaceutical companies: The development of guidelines for patient advocacy organizations in the field of rare diseases","volume":"13","author":"Stein","year":"2018","journal-title":"Orphanet J. Rare Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/4\/989\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:58:32Z","timestamp":1760194712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/4\/989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,26]]},"references-count":85,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4]]}},"alternative-id":["ijms19040989"],"URL":"https:\/\/doi.org\/10.3390\/ijms19040989","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,26]]}}}